The MAA continue to pursue the opportunity for more equitable access by the Myasthenia community to the treatment option, Rituximab/MabThera.

As this drug is currently only available through a select group of major hospital pharmacy budget (at no or little cost to the individual) or by direct funding from individuals ( at very significant costs) it is not an achievable treatment option for many people with Myasthenia. The MAA Board aim to understand more about this issue in our community and urge people to complete the following very short survey. It will take less than 60 seconds to complete! Thank you in anticipation.